Testing a Changed Immune Cell Treatment for Children With High-Grade Glioma or DIPG
Official title: IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This early study tests a treatment made from a child's own immune cells.
Read our full plain-language summary
What the trial team says
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in newly diagnosed and recurrent CD70+ Pediatric High-Grade Gliomas (pHGG) and Diffuse Intrinsic Pontine Glioma (ndDIPG)
Key facts
- Registry number
- NCT06946680
- Stage of testing
- Phase 1
- Conditions studied
- High-grade Glioma, Diffuse Intrinsic Pontine Glioma
Where it is running
This trial lists 1 site.
-
Florida
- University of Florida Health Children's Hospital (Gainesville)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.